Abstract 339P
Background
Recent literature has proposed MBSR as an intervention that can decrease symptom burden in oncologic patients. However, there is paucity of data on the effect of online-delivered interventions despite the potential of this modality to improve access and adherence to treatment. The aim of this study was to study the effects of an online MBSR intervention on BC survivors.
Methods
Women aged ≥18 years, diagnosed with stage 0-III BC at least 1 year prior to inclusion and not undergoing active treatment were invited to participate. Those with mild anxiety were randomized to an online MBSR intervention or waitlist (WL). The MBSR intervention consisted of 8 weekly sessions of meditation guided by a certified instructor. Measured outcomes included anxiety (GAD-7), depression (PHQ-9), worry about disease recurrence (CWS), fatigue (FACIT-F), insomnia (ISI), and vasomotor symptoms (MENQOL). Assessments were done at baseline, 2 months, 5 months, and 8 months.
Results
A total of 97 patients with a median age of 45 years (IQR: 40-51) and a median of 24 months (IQR: 15-36) after diagnosis were included. 66 were randomized to MBSR and 31 to WL. Most participants were married (54%), had public health insurance (49%), and were diagnosed with stage III (33%) or II (32%) BC. Linear mixed models controlling for health insurance, education, and stage showed that MSBR led to significant reductions in anxiety (GAD-7 -3.76, p<0.01), depression (PHQ-9 -4.17 points, p<0.01), cancer worry (CWS -2.59 points, p<0.05), fatigue (FACIT-F -4.15 points, p<0.05), and insomnia (ISI -4.10 points, p<0.01) at the 8 months follow-up, but not vasomotor symptoms (MENQOL score +0.51 points, p=0.42). Adjusted mean scores are shown in the Table. Table: 339P
Questionnaire | Group | Baseline | 8 months |
GAD-7 | MSBR | 10.3 | 5.6 |
WL | 11.1 | 9.4 | |
PHQ-9 | MSBR | 11.3 | 6.1 |
WL | 12.8 | 10.3 | |
FACIT-F | MSBR | 13.7 | 8.5 |
WL | 14.9 | 12.7 | |
CWS | MSBR | 14.4 | 11.0 |
WL | 14.0 | 13.6 | |
ISI | MSBR | 13.9 | 8.2 |
WL | 13.1 | 12.3 | |
MENQOL | MSBR | 4.4 | 3.1 |
WL | 3.9 | 2.6 |
Conclusions
An online MBSR intervention demonstrated a statistically significant and persistent reduction in anxiety and depression symptoms in BC survivors. This modality offers BC patients better access to interventions with the potential to improve their quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Gutiérrez-Ornelas: Financial Interests, Personal, Financially compensated role, Director: Centro Mindfulness Monterrey. A. Platas: Non-Financial Interests, Personal, Member of Board of Directors: MILC - Médicos e Investigadores en la Lucha contra el Cáncer de Mama. H.C. Verduzco-Aguirre: Financial Interests, Personal, Other, Research honoraria: Celulicity; Financial Interests, Personal, Other, Travel grants: Asofarma, AstraZeneca. C.M. Villarreal Garza: Financial Interests, Personal, Invited Speaker: MSD Oncology, Novartis, Pfizer, AstraZeneca Mexico, Lilly; Financial Interests, Personal, Research Grant: Pfizer; Financial Interests, Personal, Advisory Board: Lilly, AstraZeneca Mexico, MSD Oncology; Non-Financial Interests, Personal, Member of Board of Directors: MILC - Médicos e Investigadores en la Lucha contra el Cáncer de Mama. All other authors have declared no conflicts of interest.
Resources from the same session
424P - Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Presenter: Xichun Hu
Session: Poster session 03
425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Presenter: Blanca Tavara
Session: Poster session 03
427P - Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
Presenter: biyun Wang
Session: Poster session 03
428P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: 5-year update from the SIRI study
Presenter: Antonis Valachis
Session: Poster session 03
429P - The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Presenter: Hasan Yildirim
Session: Poster session 03
430P - Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries
Presenter: Carmen Criscitiello
Session: Poster session 03
431P - Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Presenter: Eleonora Nicolo
Session: Poster session 03
432P - Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Presenter: Lucia Navarro Berlanga
Session: Poster session 03
433P - Effectiveness and safety of vinorelbine + inetetamab + pyrotinib in ≥second-line treatment of HER2-positive metastatic breast cancer
Presenter: Wu Fan
Session: Poster session 03